70,000 Shares in AstraZeneca PLC (NASDAQ:AZN) Acquired by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 70,000 shares of the company's stock, valued at approximately $5,145,000. AstraZeneca makes up approximately 2.8% of Sivik Global Healthcare LLC's holdings, making the stock its 20th largest position.

Other large investors have also recently bought and sold shares of the company. Dynamic Advisor Solutions LLC grew its stake in AstraZeneca by 58.4% during the first quarter. Dynamic Advisor Solutions LLC now owns 13,055 shares of the company's stock worth $960,000 after buying an additional 4,811 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of AstraZeneca by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 498,831 shares of the company's stock worth $32,683,000 after acquiring an additional 5,384 shares during the last quarter. Dorsey & Whitney Trust CO LLC lifted its holdings in shares of AstraZeneca by 0.5% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 35,300 shares of the company's stock worth $2,313,000 after acquiring an additional 189 shares during the last quarter. Brandywine Global Investment Management LLC bought a new position in shares of AstraZeneca in the fourth quarter worth about $28,071,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of AstraZeneca by 13.1% in the first quarter. Farther Finance Advisors LLC now owns 6,083 shares of the company's stock worth $442,000 after acquiring an additional 706 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Price Performance

Shares of AZN stock traded down $0.81 on Friday, reaching $69.95. The company had a trading volume of 6,295,220 shares, compared to its average volume of 5,213,098. The stock has a market capitalization of $216.94 billion, a PE ratio of 28.09, a price-to-earnings-growth ratio of 1.28 and a beta of 0.38. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68. The business's 50-day moving average is $70.34 and its 200 day moving average is $70.44.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The firm had revenue of $13.59 billion during the quarter, compared to analysts' expectations of $13.71 billion. During the same quarter in the prior year, the business earned $2.06 earnings per share. The business's revenue for the quarter was up 7.2% compared to the same quarter last year. Equities research analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, BNP Paribas assumed coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 target price for the company. One research analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $85.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.